This trial will compare the efficacy of two types of chemotherapy treatments in patients who have progressed after taking osimertinib as their first line of treatment.
- Non-Small Cell Lung Cancer
1 Primary · 4 Secondary · Reporting Duration: At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days),then every 12 weeks, relative to randomization,and upto intracranial or extracranial disease progression or end of survival follow-up,whichever comes first (approximately 3 years)
Awards & Highlights
2 Treatment Groups
Treatment Arm A
1 of 2
Treatment Arm B
1 of 2
204 Total Participants · 2 Treatment Groups
Primary Treatment: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18 - 130 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What chemotherapy drugs has the FDA cleared Osimertinib (AZD9291) for use with?
"Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin has received a safety rating of 3. This is based off of the fact that this is a Phase 3 trial, which suggests that there is some evidence for efficacy and multiple rounds of data supporting safety." - Anonymous Online Contributor
Is this research project actively recruiting new participants?
"The trial is still open for recruitment, as seen on clinicaltrials.gov. This specific study was originally posted on September 12th, 2021 and was edited on October 10th, 2022." - Anonymous Online Contributor
Are there other ongoing studies that are testing Osimertinib (AZD9291) in combination with pemetrexed, cisplatin or carboplatin?
"The original trial for Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin was at City of Hope Comprehensive Cancer Center in 1997. As of now, there have been a total of 1790 completed trials and 1306 active trials. Many of these active trials are being conducted in Boston, Minnesota." - Anonymous Online Contributor
How many participants are being included in this clinical trial?
"That is accurate. The clinical trial in question, which is looking for 204 participants at 4 locations, is actively recruiting patients according to the information available on clinicaltrials.gov. The trial was originally posted on September 12th, 2021 and was last edited on October 10th, 2022." - Anonymous Online Contributor
Does this experimental treatment only test on geriatric patients?
"According to the inclusion criteria posted for this clinical trial, eligible patients must be between 18 and 130 years old. There are 143 trials for patients under the age of 18 and 3206 for people over 65." - Anonymous Online Contributor
If I want to participate in this clinical trial, how many different city locations do I have to choose from?
"Currently, there are 4 enrolling sites for this study with more to come. The sites are situated in cities including Boston, Minneapolis and Silver Spring. If you enroll in the study, it is best to choose the clinic that is most convenient for you to reduce travel time and effort." - Anonymous Online Contributor
What type of cancer do doctors most often treat with Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin?
"Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin is most often used to treat lymphoma, non-hodgkin. However, it has also shown efficacy in the treatment of malignant neoplasms, advanced sarcoma, and neoplasm metastasis." - Anonymous Online Contributor
Might I be eligible to join this clinical trial?
"This study is for people with [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) who are 18 to 130 years old. There are 204 spots in the trial. To join, participants must: - Be male and willing to use contraception- Have a life expectancy of more than 12 weeks- Have stage IIIB or IIIC cancer that can't be cured with surgery or stage IVA or IVB cancer that has come back- Be in good enough health that they can take part in the trial- Be female and using contraception or not be able to have children" - Anonymous Online Contributor